Cellectar Biosciences (NASDAQ:CLRB) Earns Sell Rating from Analysts at StockNews.com
Equities researchers at StockNews.com assumed coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Cellectar Biosciences Price Performance Shares of Cellectar Biosciences stock opened at $0.26 on Tuesday. The business’s 50 day simple […]
Equities researchers at StockNews.com assumed coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Cellectar Biosciences Price Performance Shares of Cellectar Biosciences stock opened at $0.26 on Tuesday. The business’s 50 day simple […]
